Report cover image

Harrow Inc (HROW) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Dec 31, 2025
Length 52 Pages
SKU # GBDT20700031

Description

Harrow Inc (HROW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Harrow Inc (Harrow) is a leading pharmaceutical company specializing in the ophthalmic healthcare sector. The company's primary activities involve the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products. Harrow's product portfolio includes a wide range of FDA-approved prescription and non-prescription pharmaceuticals for treating various eye conditions, such as dry eye disease, allergies, infections, glaucoma, and other ophthalmic inflammatory conditions. The company markets its products under the Harrow name and also operates ImprimisRx, a leading ophthalmology-focused pharmaceutical-compounding business. Harrow's products are used by doctors, hospitals, and ambulatory surgical centers (ASCs) across various industries. The company operates across the US. Harrow is headquartered in Nashville, Tennessee, the US.

Harrow Inc Key Recent Developments

Nov 24,2025: Harrow to Present at Two Investor Conferences in December
Nov 18,2025: Harrow Completes Acquisition of Melt Pharmaceuticals
Oct 06,2025: ImprimisRx Announces Leadership Changes
Sep 25,2025: Harrow Unveils Harrow Access for All Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

52 Pages
Section 1 - About the Company
Harrow Inc - Key Facts
Harrow Inc - Key Employees
Harrow Inc - Key Employee Biographies
Harrow Inc - Major Products and Services
Harrow Inc - History
Harrow Inc - Company Statement
Harrow Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Harrow Inc - Business Description
R&D Overview
Harrow Inc - Corporate Strategy
Harrow Inc - SWOT Analysis
SWOT Analysis - Overview
Harrow Inc - Strengths
Harrow Inc - Weaknesses
Harrow Inc - Opportunities
Harrow Inc - Threats
Harrow Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Harrow Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Harrow Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 24, 2025: Harrow to Present at Two Investor Conferences in December
Nov 18, 2025: Harrow Completes Acquisition of Melt Pharmaceuticals
Oct 06, 2025: ImprimisRx Announces Leadership Changes
Sep 25, 2025: Harrow Unveils Harrow Access for All Program
Sep 15, 2025: Harrow Announces Agenda and Speakers for Investor & Analyst Day
May 14, 2025: Harrow to Present at Two Investor Conferences in May
Mar 11, 2025: Harrow Announces Execution of Five-Year Strategic Supply and Development Agreement for TRIESENCE
Jan 07, 2025: Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
Nov 21, 2024: Harrow’s Imprimisrx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in Imprimisrx, LLC v. Osrx, Inc.
Nov 14, 2024: Harrow Releases Q3 2024 Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Harrow Inc, Key Facts
Harrow Inc, Key Employees
Harrow Inc, Key Employee Biographies
Harrow Inc, Major Products and Services
Harrow Inc, History
Harrow Inc, Subsidiaries
Harrow Inc, Key Competitors
Harrow Inc, Ratios based on current share price
Harrow Inc, Annual Ratios
Harrow Inc, Annual Ratios (Cont...1)
Harrow Inc, Annual Ratios (Cont...2)
Harrow Inc, Interim Ratios
Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Harrow Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Harrow Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Harrow Inc, Performance Chart (2020 - 2024)
Harrow Inc, Ratio Charts
Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Harrow Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.